Multitarget Virtual Screening for Drug Repurposing in COVID19 by Sorzano, Carlos Óscar S. et al.
Multitarget virtual screening for drug
repurposing in COVID19
C.O.S. Sorzano1, E. Crisman2, J.M. Carazo1, R. León2
July 16, 2020
(1)Biocomputing Unit, National Center for Biotechnology (CSIC), c/Darwin, 3,
Campus Universidad Aut’onoma, 28049 Cantoblanco, Madrid, Spain.
(2)Hospital de La Princesa, c/Diego de León, 62, 28006, Madrid, Spain
Abstract
Therapeutic or preventive research for coronavirus SARS-CoV2 is an
extremely active topic of research since its outbreak in January 2020. In
this paper we report the results from a virtual drug screening analysis
that, to the best of our knowledge, is the widest work in terms of target
proteins and compound library. Our study was focused on the repur-
posing of currently commercialized drugs, and especially those that can
interact with multiple viral proteins and several binding sites within each
protein. Additionally, we performed a second virtual screening analysis in
which we compared our results to the predicted binding affinities for the
drugs currently in clinical trials. We show that the best molecules in our
screening compares favourably to those in clinical trials, suggesting their
suitability for therapeutic or preventive applications.
1 Introduction
Coronavirus SARS-CoV-2 has largely affected our society since Jan. 2020, and
many scientific efforts have been quickly reoriented to find therapeutic and pre-
ventive treatments to diminish its impact. Structural biology and computational
drug screening can accelerate the search for drugs by elucidating the three-
dimensional structure of the viral proteins (Structural Biology) and predicting
possible compounds or compound fragments that could interact with these pro-
teins (computational drug screening). Drug repurposing is especially interesting
in this endeavour as their safety and secondary effects are well characterized for
other applications.
Virtual screening is typically performed by analyzing the catalytic site of a
protein of interest and looking for drug fragments that interact with it. These
drug fragments can then be appropriately linked and their ADME properties
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optimized. This process is long, although rewarding as it may ultimately lead to
a commercial product from which the company may benefit. It is more difficult
to predict the effectiveness of a binding in an allosteric site. Moreover, because
it is difficult to determine the relationship between the allosteric site and the
catalytic site.
Most virtual screening works so far has followed an approach similar to the
one described above. Only that instead of looking for new molecules, they search
for the interaction of existing molecules. However, they still concentrate in one
or two proteins, and one or two sites within these proteins (Chen et al., 2020;
Contini, 2020; Elmezayen et al., 2020; Jin et al., 2020; Kandeel and Al-Nazawi,
2020; Mittal et al., 2020; Muralidharan et al., 2020; Sekhar, 2020; Smith and
Smith, 2020; Ton et al., 2020; Wang, 2020; Xu et al., 2020). Additionally, to
speed up the process, they have constructed homology models for the target
viral proteins instead of having to wait for the experimental determination of
these targets (Arya et al., 2020; Chen et al., 2020; Contini, 2020; Elfiky, 2020;
Elmezayen et al., 2020; Sekhar, 2020; Smith and Smith, 2020; Wang, 2020; Xu
et al., 2020). The 3CL protease has been the main target of previous works. This
is a very important protein for the virus replication. However, hindering the
virus cycle at any of its steps would reduce the infection speed, and eventually
even stop it by allowing the immune system to have time to fight the virus.
At present there are over 100 atomic models of the virus proteins at the
Protein Data Bank (Rose et al., 2011). Unfortunately, there is not an atomic
model for all viral proteins and complexes. And, on the other side, many of
these 100 models are partially redundant as they describe the same protein or
complex as solved by several structural groups.
One of the main problems with a treatment targeting a single viral protein
is that the virus may mutate and become immune to the treatment. If a new
treatment is found and the virus mutates again, a multirresistant virus could be
selected. An alternative approach is to find a multidrug treatment that blocks
the virus functions at several points along its cycle, making less likely that the
virus successfully mutates at several places in order to escape the treatment.
Analogously, a single compound that could interact with the virus at several
places would be at an advantageous position as it also makes the resistance
raising problem more difficult. Additionally, the prediction problem of allosteric
sites is of less importance in this virus blocking application: if we find a molecule
that interacts at several places of a target protein, we can foresee that it will
hinder its normal function even if we are not able to accurately predict its effect
on the catalytic site.
One of the main criticisms to virtual screening is that it does not accurately
reproduce reality as experimentally measured binding affinities are normally dif-
ferent from those computationally predicted. Notwithstanding, computational
means have been found to be rather meritorious is some tasks (an accuracy of
86% in the identification of binding sites (Halgren, 2009), or hit success between
1 and 40% for molecules at the top of the list (Slater and Kontoyianni, 2019)).
This “bad quality” results are also found in other scientific domains. Specif-
ically, in data analysis, many weak classifiers can be gathered into a strong
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classifier (Polikar, 2007). Assume that we have to classify objects into class A
or B (for the sake of argument, let us assume that both kinds of objects are
equally likely). We know how to construct classifiers whose classification accu-
racy is only 51%, they are just 1% better than a random classification. However,
if we construct 20,000 of these weak classifiers, we may accurately determine the
class of the object simply by evaluating the difference in the number of votes for
classes A and B. This is at the basis of some of the state-of-art classifiers as ran-
dom forests (Breiman et al., 1993; Breiman, 2001) or other ensemble classifiers
(Bishop, 2006). Note that this extreme case of such a weak classifier has been
set only as an example, and that virtual screening is in a much better situation.
Joining the specific application of viral cycle blocking (in which as many
bindings as possible are preferred) and following an approach similar to the one
of ensemble clustering (in which algorithmic errors are compensated by multiple
predictions), we have devised a drug repurposing strategy in which, for all viral
proteins whose 3D structure is experimentally determined, we computationally
find up to 10 possible binding sites. Then, we look for small molecules that are
predicted to bind these sites. Finally, we sort the molecules according to these
two criteria: binding affinity and number of binding sites predicted by molecule.
This multitarget approach is, in a way, similar to that followed by Zhou et al.
(2020). In both approaches, we use experimentally determined structures for the
viral proteins and several atomic models for each one of them. However, there
are some important differences: 1) (Zhou et al., 2020) analyzed 7 viral proteins
and 1 binding pocket per target, this binding pocket was manually selected;
we analyzed 10 proteins, and almost 300 binding sites predicted by Schrödinger
sitemap (one of the most established computer programs for this task); 2) (Zhou
et al., 2020) used Rosetta GAligandDock (an unpublished docking protocol in
Rosetta) for the ligand docking, while we used Schrödinger glide, that has
over 3,000 citations (this change in the program may explain the differences in
the predicted binding affinities); 3) they explored a wide range of compounds
from DrugBank, while we have focused in compounds approved by the FDA and
other world drug agencies, and we have given especial attention to already cheap
and commercialized drugs that could immediately be used for a clinical trial;
4) we have explicitly looked for drugs that bind several proteins simultaneously
(rather than they bind to the different atomic models of the same protein as in
Zhou et al. (2020)).
From the previous analysis several molecules outstand from the rest of com-
pounds. We then compared these molecules in a second virtual screening anal-
ysis with those currently in clinical trials for COVID19. We show that the
compounds found in the first analysis compare favourably to the ones in clinical
trials. We also draw some interesting results applicable to the compounds in
clinical trials. Finally, we report a list of compounds that are widely available,




The following process has been conducted in our workflow engine Scipion (de la
Rosa-Trev́ın et al., 2016), through an extension that we have recently performed.
The whole process required more than 2,000 Scipion protocols, i.e., the largest
Scipion project ever performed, and some of the sets involved more than 9
million entries. Without the help of this workflow engine, it would have been
very difficult to carry out this massive analysis.
Target reparation
We analyzed all viral proteins for which an experimentally determined three-
dimensional structure was known. For each of the target molecules, we analyzed
several of its atomic models, with a total of 30 atomic structures being analyzed.
Table 1 shows the list of PDB codes for each one of the studied viral proteins.
S2 is a protein of the virus spike. The spike contains the Receptor Binding
Domain (RBD), which interacts with the Angiotensin Converter Enzyme 2 dur-
ing cell infection. Non-structural proteins 10 and 16 make the viral RNA to
become unnoticed by the cell foreign RNA recognition system, NSP3 is respon-
sible for cutting and untagging viral proteins, NSP5 is a papain-like protease,
NSP9 helps to construct pores in the cell nucleus membrane, NSP15 is an en-
doribonuclease in charge of removing viral RNA, NSP12 is an RNA polymerase,
and the complex NSP12&7&8 is the RNA replication complex. The virus cycle
and possible points to interfere with drugs are reviewed in Guy et al. (2020).
Viral protein PDB codes
Spike 6VSB, 6VXX, 6VYB
S2 6LXT
RBD/ACE2 6M17, 6M0J, 6LZG
RBD 6W41
NSP10 & 16 6W75, 6WJT
NSP3 6W6Y, 6VXS, 6W02, 6W9C
NSP9 6W9Q, 6W4B




NSP12 & 7 & 8 7BV1, 7BV2
Table 1: Viral proteins and PDB codes used for virtual screening. RBD: Re-
ceptor Binding Domain. ACE2: Angiotensin Converter Enzyme 2. NSP: Non-
structural protein
For each target molecule, we called Schrödinger prepwizard for a pH of 7
and a pH range of 2. We asked the program to fill side chains and loops, create
bonds between proximal sulfurs, convert the selenomethionines to methionines,
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delete and re-add hydrogens, add the cap termini, remove water molecules,
and organic molecules used for co-crystallization. We computed the network of
hydrogen bonds and the protonation states with propka (Olsson et al., 2011).
Finally, we performed a restrained minimization using the OPLS force field 3
with an RMSD convergence threshold of 0.3 Å.
For each one of the prepared targets, we have predicted at most 10 binding
sites using Schrödinger sitemap program. This program has an accuracy of
86% in the identification of binding sites (Halgren, 2009). We removed from the
analysis those binding sites whose binding score was smaller than 0.8. Around
each binding site, we prepared a search grid with an inner box of 10Å and an
outer box of 30Å.
We repeated the same process for each of the domains of these 30 proteins.
In total, we analyzed 297 binding pockets whose binding score was above 0.8.
Fig. 1 shows the numerical description made by Schrödinger sitemap for this
set of binding pockets.
Compound library preparation
For the compound library in the first screening we have taken all compounds
approved by the FDA and other world drug agencies as listed by the ZINC15
database (FDA and world-non-FDA) (Sterling and Irwin, 2015). This library
comprises 5,905 compounds. We then prepared these compounds using Schrödinger
ligprep. We used Epik for the generation of the ligand ionization (pH of 7 and
an pH range of 2) and tautomeric states. We used OPLS3e force field for the
ligand preparation. This process may duplicate some of the compounds depend-
ing on possible ionization states along the pH range. This step expanded the
5,905 input compounds to 9,723 derived compounds.
For the compound library in the second screening, we have taken all com-
pounds currently in clinical trials as listed in ClinicalTrials.gov, the set of the
top scoring compounds in our first screening, and a random subset of the ZINC
FDA and world-non-FDA catalogs of the same size as the other two subsets
(clinical trials plus top scoring in the first screening).
1st virtual screening
For each binding site of each target, we have performed a two-level docking
prediction using Schrödinger glide. In both stages we have used a flexible
docking (confgen, Watts et al. (2010)). In the first stage we used a low docking
precision (HTVS). For each compound and site comparison, we allowed 5,000
initial poses per ligand and kept up to 5 of the best poses. We chose 2% of
the poses coming out of the first docking analysis and removed the redundancy
(several poses) keeping only 1 pose per ligand. With the surviving set of ligands,
we performed a second docking stage with a more precise docking model (SP).
The number of initial poses and kept poses were the same as for the first docking
stage. We kept the best 10% of the poses sorted by binding affinity. Then, for
each protein target we gathered the results of all the second docking rounds
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in each one of its binding sites. From this gathering, we kept 20% of the best
poses.
2nd virtual screening
The goal of the 2nd virtual screening was to compare the results of the com-
pounds found in the first virtual screening with respect to the results predicted
for compounds already in clinical trials against COVID19. The compound li-
brary of this virtual screening was much smaller and made of three subsets: 1)
top compounds found in our first screening, 2) compounds in clinical trials, 3)
random subset of the ZINC FDA and world-non-FDA catalogs with the same
size as subsets 1 and 2. This third subset will give a background distribution
for compounds that, in general, are not expected to especially interact with the
viral proteins.
For the second screening we used the more precise docking model (SP) and
there was no filtering of poses by docking score so that we can see the full
distribution of predicted values for all compounds in the compound library.
The rest of parameters remained equal to those used in the first screening.
3 Results
1st virtual screening
Table 2 shows a summary of the results coming out the massive virtual screening
with multiple viral targets and multiple structures per target. We report on the
number of unique compounds found to interact with the different proteins, the
average number of binding sites per structure, the average number of compounds
per site and the range of affinity bindings and ligand efficiencies. We remind
that for each target protein we also predict binding sites for each of its individual
domains so that, even if we ask the program a maximum of 10 possible binding
sites, the average number per structure can be a bit higher.
From this analysis, we can already learn some interesting results:
• There is a wide range of possible binding sites among the viral proteins
(average number of binding sites per structure). The ones more difficult
to attack are the one forming nucleus pores (NSP9), the nucleocapsid, and
the two proteases (NSP3 and NSP5). On the other side, the ones with
more possible binding sites are the endoribonuclease (NSP12 & 7 & 8),
the methyltransferase complex (NSP10 & 16), and the spike.
• The two proteases have very few possible binding sites (2-3), but very
promiscuous, capable of interacting with many different partners (average
number of unique compounds per site above 100). This is, probably, a
consequence of their physiological function of having to interact with many
different protein substrates.
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It is remarkable that most previous studies on drug repurposing has focused
on the papain-like protease, instead of the more accessible spike or receptor
binding proteins. This massive study may suggest new research directions for















Spike 786 10.3 (15,300) 76.3 [-11.34, -7.57] [-0.88,-0.11]
S2 97 3.4 (1,100) 28.5 [-10.78, -8.56] [-1.27, -0.12]
RBD/ACE2 409 7.2 (7,500) 56.8 [-10.75, -7.54] [-1.11, -0.12]
RBD 211 6.8 (2,000) 31.0 [-9.12, -6.93] [-1.02, -0.10]
NSP10 & 16 423 10.4 (2,500) 40.7 [-9.97, -7.03] [-1.23, -0.11]
NSP3 350 2.7 (1,100) 129.6 [-12.96, -7.18] [-1.01, -0.11]
NSP9 98 1.5 (200) 65.3 [-8.63, -6.29] [-0.80, -0.09]
NSP5 413 2.1 (3,700) 196.7 [-10.88, -6.41] [-0.81, -0.09]
NSP15 213 6.0 (1,700) 35.5 [-10.66, -7.27] [-0.92, -0.11]
Nucleocapsid 147 2.0 (2,300) 73.5 [-10.91, -8.49] [-1.04, -0.13]
NSP12 475 11.2 (3,400) 42.4 [-9.55, -7.00] [-0.91, -0.11]
NSP12 & 7 & 8 510 13.9 (2,700) 36.7 [-11.14, -7.00] [-0.99, -0.10]
Table 2: Summary of the virtual screening performed on several structures of
the viral proteins. We report the number of unique compounds found to interact
with the macromolecule, the average number of binding sites per PDB structure
(and the total volume, on average, for all sites in the target), the average number
of unique compounds per binding site, and the range of affinity bindings and
ligand efficiencies.
The first screening resulted in 12,503 poses of 2,031 compounds, distributed
along the 297 possible binding sites of the 30 target structures. Suppl. Fig. 2
shows the docking score (binding affinity) and ligand efficiency of these poses.
We also analyzed the number of poses for each one of the compounds (remind
that each compound may occupy up to 5 different poses in the same binding
site depending on its binding affinity). The most frequently observed value is
1 pose, the median is 3, and 95% of the compounds occupy less than 22 poses.
However, 5% of the compounds have more than 22 poses, and 1% more than
63. As argued in the introduction, this set of molecules with many binding sites
are the most interesting ones.
This virtual screening produces a formidable amount of data (the raw results
are available as Suppl. Material). In order to combine the two requirements
(high affinity and high number of binding sites) we summarize the output data
by taking the best binding affinity for each pair compound-site. Then, for each
pair compound and target protein, we added all the binding affinities. Table 3
shows these aggregated values as well as the number of sites occupied by each
compound. In this table we show a cephalosporin and a quinolone. However,
these families of molecules systematically appeared interfering with the NSP10
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& 16 or NSP12 & 7 & 8 complexes (the full results are available as Suppl.
Material).
2nd virtual screening
The second virtual screening aims at comparing the top drugs coming out from
the first analysis (14 compounds) and the ones currently in clinical trials (159
compounds; both together they are called the treatment group and it is formed
by 173 compounds) with respect to a random subset of compounds approved
by the FDA or world-non-FDA agencies (we refer to this random subset as the
control group and it is also made of 173 compounds). For each compound we
kept the best 5 poses in each one of the possible binding sites. Overall, the
analysis resulted in 418,605 poses (that are the best 5 poses of all the ionized
and tautomerized versions of the compounds in all studied binding sites). Fig.
3 shows the binding affinity distribution for both groups. As can be seen, both
distributions significantly overlap. However, a two-sample Kolmogorov-Smirnov
test gives a p-value of 0.006671. The median values for both distributions are
-8.11 (treatment) and -7.70 (control). Actually, the most interesting part, from
a therapeutic perspective, of this distribution is the region below -8 kcal/mol.
This small difference between both distributions is enlarged if the bottom 1%
poses are considered (-11.44 for the treatment group, -10.33 for the control
group).
Only 39 pairs of treatment compound-binding site had a better binding
affinity than the 1% percentile of the control group. Among these pairs, we
found (in parentheses we have given the structure it fits in and the binding
pocket number assigned during our analysis):
• From our first virtual screening: FAD (14 poses, 1 binding site of NSP3
(6W021), 1 of S2 (6LXT2)), NADH (8 poses, 1 binding site of NSP3
(6W021)), Coenzyme A (5 poses, 1 binding site of NSP3 (6W021)), Can-
grelor (7 poses, 1 binding site of NSP3 (6W021)), Isovuconazole (3 poses,
1 binding site of NSP3 (6W021)), Integrilin (2 poses, 1 binding sites of
NSP3 (6W021) and the Spike (6V SB1)).
• From the compounds in clinical trials: None
The most prominent family among the compounds in clinical trials are those
derived from heparin, and these have already proved to be effective in the treat-
ment of COVID19 (Thachil, 2020). It could be because 1) the drug interacts
with the virus, or 2) because the drug ameliorates or prevents some of the lesions
caused by the virus. In this work we have shown that the first hypothesis is true
(which does not mean that the second is not also true). It is interesting that
one of the outstanding molecules in the clinical trial pipeline is a cephalosporine
(ceftaroline) confirming the systematic appearance of this family of molecules
in our first virtual screening.
It is also very interesting that all the clinical trials listed above are addressing
just 2 binding sites of a single complex (the RNA polymerase).
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Remdesivir has already been shown to shorten the recovery time in groups
of COVID19 patients (Grein et al., 2020). In our study it appears as one of
the drugs with a medium potency in its iteraction with the virus (best binding
affinity -8.68 kcal/mol). Hydroxychloroquine has already been reported to have
a positive effect in-vitro although its clinical application has been abandoned
due to its seemingly increased risk of death. Its highest binding affinity in all
possible target sites is -7.39 kcal/mol. For the sake of comparison, from now
one we will only count those interactions with a binding affinity better than -8
kcal/mol. Remdesivir has 3 binding sites above this level on 3 different proteins.
Above the level of remdesivir in the set of clinical trials, we have (best binding
affinity [kcal/mol], BS=binding site): Umifenovir (-8.01, 1 BS), Clavulanic acid
(-8.09, 1 BS), Captopril (-8.20, 1 BS), Amoxicillin (-8.51, 2 BS), Piperacillin
(-8.56, 2 BS), Atorvastatin (-8.7, 1 BS), Linagliptin (-8.73, 2 BS), Nintedanib (-
8.77, 1 BS), Omeprazole (-8.80, 4 BS), Tinzaparin (-8.92, 1 BS), Heparin (-8.92,
1 BS), Curcumin (-9.12, 3 BS), Anakinra (-8.55, 1 BS), Folic acid (-9.30, 3 BS),
VazegepantBHV3500 (-9.79, 7 BS), Telmisartan (-9.85, 6 BS), Metenkefalin (-
9.90, 12 BS), Deferoxamine (-9.90, 2 BS), Famotidine (-9.90, 3 BS), Isoprinosine
(-9.97, 3 BS), AT001 (-10.14, 2 BS), Cobiscitat (-10.17, 11 BS), Methotrexate
(-10.27, 7 BS), Defibrotide (-10.29, 2 BS), IMU838 (-10.44, 3 BS), Danoprevir
(-10.46, 3 BS), Doxycycline (-11.44, 2 BS), Ceftaroline (-11.45, 6 BS). These are
28 out of the 159 clinical trials (18%).
Above the level of remdesivir in our first virtual screening: Plazomycin (-
9.23, 14 BS), Neomycin (-10.06, 14 BS), Atosiban (-10.22, 24 BS), Capreomycin
(-10.15, 15 BS), Isovuconazole (-10.45, 23 BS), Cefoporazone (-10.88, 6 BS),
Ceftolozane (-10.93, 6 BS), Cangrelor (-10.94, 22 BS), Integrilin (-11.02, 8 BS),
Coenzyme A (-11.36, 13), NADH (-12.44, 8), FAD (-12.96, 12).
From the top compounds (both in number of binding sites and binding affini-
ties) of the second virtual screening, we narrowed the list to those commercial
compounds whose price in the public market is smaller than 15 euros and they in-
teract with at least 3 binding sites (we removed heparin as it caused Schrödinger
glide to fail). For these compounds, we run another round of virtual screening,
this time with the XP accuracy (the most accurate analysis of glide). Table
4 shows the aggragated binding affinities. We find a few antibiotics (neomycin,
amoxicillin+clavulanic acid), non-steroid antiiflamatories (indomethacine), an-
tihypertensives (telmisartan, ramipril, and atorvastatin), and a proton-pump
inhibitor (omeprazole). There are also some rather common compounds (folic
acid, coenzyme A, NADH, and FAD) that are considered nutritional supple-
ments (FAD is not commercialized as a supplement). Coenzyme A, NADH and
FAD can be derived from their vitamin precursors, B5, B3, and B2, respectively.
4 Conclusions
After several rounds of screening with different accuracy models for the bind-
ing affinity (from least to most accurate), a number of compounds has consis-
tently outperformed the rest. All the compounds in the first virtual screening
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were among the best matching compounds in the second round. The fact that
many of the compounds currently in clinical trials were also among the top
compounds showed the capacity of the virtual screening to identify interesting
compounds (compounds currently in clinical trials have been selected because
they have already shown some positive features either in in vitro studies or
with patients). Very interestingly, some of the compounds in clinical trials
(Amoxicillin+Clavulanic acid, Heparin, Indomethacin, Telmisartan, Ramipril,
and Atorvastatin) have high binding affinities (¡-8 kcal/mol) to several binding
sites and several target proteins. This fact casts a positive forecast on these
clinical trials. On the other side, some of the other clinical trials seem to be
targeting a single protein (Levofloxacin, Naproxen, and Omeprazole).
Among the most prominent compounds, we have detected Neomycin that
is a very cheap antibiotic widely available and produced by many independent
companies, which guarantees its supply. The fact that it is an antibiotic may
help the acute pneumonia caused by the virus. If we need to tackle hypertension
or inflammatory response, we have also identified that some of the compounds
currently in clinical trials (telmisartan, ramipril, and atorvastatin, for the hy-
pertension; and naproxene and indomethacine, for the inflammation) seem to
interact with the viral proteins, which might be a help in order to reduce, not
only the virus effects, but also its infection.
We have also identified FAD, NADH+NA and Coenzyme A, and to a smaller
extent, folic acid. These compounds largely outperform the drugs currently
in clinical trials in terms of binding affinity to viral proteins and variety and
potency of binding sites. They are also found in the normal metabolism of cells.
NADH, Coenzyme A, and folic acid are sold as nutritional supplements. If not in
their pure form, their precursors are Vitamins B2 (FAD), B3 (NADH+NA) and
B5 (Coenzyme A), which are also normally sold as nutritional complements.
We are conscious that these compounds can be taken up by any other cell
in the body. However, globally raising their concentration, and given their
high affinity for the viral proteins, could be used as a preventive treatment in
healthy patients. Their use in COVID19 affected patients may also slow down
the growth rate of the virus.
Some of the compounds coming out from the first screening are difficult to
handle in a widely adopted manner. For instance, Cangrelor has the highest
number of binding sites and high affinity. However, Cangrelor is a rather ex-
pensive drug, that is continually perfused in a hospital environment (in part
because its pharmacokinetic half-life is between 3 and 6 minutes). Similar com-
ments on the price, ease of wide application, pharmaceutical form, or diversity
of supply could be made on other drugs in the list of drugs in clinical trials or
drugs in the outcome of the first screening.
In this paper we have taken the position of looking for compounds that
are cheap, widely available, with low toxicity (neomycin is widely used at the
moment), and binding to many sites and many viral proteins. Although, there
is no guarantee of success, this fact is very suggestive as a predictor of a possible
success in a clinical trial.
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Figure 1: Matrix scatter plot of the variables describing the binding sites after
filtration. The numbers in the upper left triangle is the correlation between
variables. The parameter description of the binding sites are: score, phobic,
exposure, size, balance, contact, donacc, enclosure, philic, volume, dscore. Their
meaning is described in Schrödinger sitemap user’s manual.
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Figure 2: Affinity binding (docking score), ligand efficiency, and pose count











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Affinity binding for the treatment group (blue) and control group
(red) of the second virtual screening.
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